Review by the US Court of Appeals for the Fourth Circuit of Amgen’s Enbrel patent strategy could clarify that acquisitions of rights to pending patent applications receive no categorical exemption from antitru... (more story)

The Food and Drug Administration's handling of confidential commercial information in foodborne illness investigations misapplies trade secret law, advocates tell MLex, granting broad protections for informati... (more story)

OpenAI’s failed bid to keep its GPT trademark in the EU shows the difficulty that technology companies face in protecting terms that become industry vocabulary. The dispute, which follows the rejection of Open... (more story)

Japan’s finalized generative AI principles code gives AI providers clearer boundaries around what they are expected to disclose, while putting more substance around what it means to “explain” when they do not.

A summary judgment Friday clarified one side of an important boundary for biological patent deposits — public availability does not create a public license. But the question of whether Inari Agriculture's cond... (more story)

Third-party litigation funders have suffered setbacks in a disclosure fight that includes patent disputes, with the USITC considering new requirements alongside action by states, Congress and a federal rules c... (more story)

The US Patent and Trademark Office determined last week that a request for ex parte re-examination of a Xiamen PVTECH Corp. patent does not raise a substantial new question of patentability, an early example o... (more story)

India's Patent Office is putting formal rules around the use of artificial intelligence across patent examination while drawing a line against allowing AI to replace examiner judgment. The safeguards look robu... (more story)